BERLIN — The antibody drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) took an important step into the early breast cancer setting, based on new findings from two trials presented at the ...
Please provide your email address to receive an email when new articles are posted on . Findings showed an overrepresentation of Black, Asian and American Indian/Alaskan Native race among people with ...
AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate (ADC) Enhertu has chalked up another win in an early breast cancer setting, this time besting Roche’s Kadcyla in a phase 3 study. Enhertu ...
Clinical Trials Arena on MSN
Northwell Health and START open early-phase cancer trial facility
The centre is equipped with a dedicated research team, six private exam rooms, 14 infusion bays, and a pharmacokinetic lab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback